MA52226B1 - Nouveaux analogues de glp-1 - Google Patents
Nouveaux analogues de glp-1Info
- Publication number
- MA52226B1 MA52226B1 MA52226A MA52226A MA52226B1 MA 52226 B1 MA52226 B1 MA 52226B1 MA 52226 A MA52226 A MA 52226A MA 52226 A MA52226 A MA 52226A MA 52226 B1 MA52226 B1 MA 52226B1
- Authority
- MA
- Morocco
- Prior art keywords
- analogs
- present
- glp
- analogues
- action
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title abstract 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne de nouveaux analogues de peptide-1 de type glucagon (glp-1) (7-37) ayant une séquence d'acides aminés avec leu ou ile au niveau de l'extrémité c-terminale. Les nouveaux analogues sont des agonistes puissants de glp-1 ayant un effet indésirable réduit et une durée d'action améliorée. La présente invention concerne en outre des dérivés acylés des nouveaux analogues qui ont en outre une puissance et une durée d'action améliorées et sont appropriés pour une administration par voie orale. Les analogues selon la présente invention peuvent être utiles dans le traitement du diabète et de l'obésité.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821013109 | 2018-04-05 | ||
| PCT/IB2019/052835 WO2019193576A1 (fr) | 2018-04-05 | 2019-04-05 | Nouveaux analogues de glp-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52226A MA52226A (fr) | 2021-02-17 |
| MA52226B1 true MA52226B1 (fr) | 2022-08-31 |
Family
ID=83280018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA59093A MA59093B1 (fr) | 2018-04-05 | 2019-04-05 | Nouveaux analogues de glp-1 |
| MA52226A MA52226B1 (fr) | 2018-04-05 | 2019-04-05 | Nouveaux analogues de glp-1 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA59093A MA59093B1 (fr) | 2018-04-05 | 2019-04-05 | Nouveaux analogues de glp-1 |
Country Status (1)
| Country | Link |
|---|---|
| MA (2) | MA59093B1 (fr) |
-
2019
- 2019-04-05 MA MA59093A patent/MA59093B1/fr unknown
- 2019-04-05 MA MA52226A patent/MA52226B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA59093B1 (fr) | 2024-05-31 |
| MA52226A (fr) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202306729B (en) | Novel glp-1 analogues | |
| MA31242B1 (fr) | Co-agonistes des recepteurs du glucagon/glp-1 | |
| AR092388A1 (es) | Formulaciones de anticuerpo y proteina | |
| PE20142332A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| AR104932A1 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| RU2013148537A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| JP2002526454A5 (fr) | ||
| RU2017146657A (ru) | Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона | |
| RU2020109881A (ru) | Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита | |
| RU2020112302A (ru) | Соединения для уменьшения вязкости биологических композиций | |
| CO2025004790A2 (es) | Anticuerpo anti-il-1r3 humanizado y métodos de uso | |
| MA52226B1 (fr) | Nouveaux analogues de glp-1 | |
| CO6341479A2 (es) | Péptidos agonistas de crhr2 y usos de estos | |
| AR127860A2 (es) | Formulaciones de péptidos terapéuticos agonistas del receptor (glp-1) / glucagón | |
| CA2593201C (fr) | Methode de traitement ou de prevention de la deterioration, de blessure ou de dommage tissulaire engendre par une maladie neuro-degenerative, degenerative musculaire ou degenerative neuro-musculaire ou permettant de restaurer un tissu altere par une telle maladie | |
| EP2890390A2 (fr) | Traitement de l'arthrose par les hormones incrétines ou leurs analogues | |
| US10105442B2 (en) | Treatment of diabetes type 1 using GLP-1 and anti-IL-21 | |
| ES2621332T3 (es) | PACAP para el tratamiento de infecciones virales en organismos acuáticos | |
| EA200800181A1 (ru) | Фармацевтическая композиция glp-1 | |
| Gault et al. | GIP-based therapeutics for diabetes and obesity | |
| EA202092017A1 (ru) | Новые аналоги glp-1 | |
| EA202290107A1 (ru) | Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1 | |
| WO2024056492A1 (fr) | Compositions destinées à être utilisées dans le traitement du diabète ou de l'obésité | |
| FR3128958A1 (fr) | Composés peptidiques cycliques agonistes du récepteur kiss1r et leurs utilisations thérapeutiques | |
| KR20250112294A (ko) | 위장관 및/또는 내분비 장애 치료를 위한 galr2 작용제의 용도 |